A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.

Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable.

Ark Investment Management founder Cathie Wood has been seeing massive money flowing into five of the seven ETFs lineup in recent months.

Revenue expected to grow 32.10% next year. Earnings estimated to increase 49.20% next year.